Event DAS-444Ø6-6 soybean is genetically modified (GM) to provide tolerance to 2,4-diclorophenoxyacetic acid (2,4-D), glyphosate, and glufosinate herbicides through expression of the AAD-12, 2mEPSPS, and PAT proteins, respectively. DAS-444Ø6-6 soybeans were evaluated for safety in subchronic rat feeding studies. The results from two previous subchronic rat feeding studies evaluating diets formulated with 20% inclusion of DAS-444Ø6-6 soybean meal (the latter also containing DAS-444Ø6-6 derived hulls and oil) did not show any treatment-related adverse effects. In 2017, to comply with recent guidance from EFSA, a third 90-day rat feeding study was conducted with Sprague-Dawley rats (16/sex/group) with diets formulated either with 15% or 30% w/w of toasted DAS-444Ø6-6 soybean meal. DAS-444Ø6-6 soybean hulls and oil were also added to the transgenic test diets at 1% or 2% w/w and 1.35% or 2.7%, respectively, for the low-and high-dose groups. No toxicologically significant effects were observed under the conditions of this study.
Introduction
Following the adoption of the regulation (EU) 503/2013 in Europe, a 90-day oral toxicity study in rodents on whole genetically modified (GM) food/feed is required for all new GM transformation events (EC, 2013) . This new EU legal requirement changes the study design from a hypothesis-driven case-by-case exercise, as indicated previously by the European Food Safety Authority (EFSA), into a mandatory requirement for the safety evaluation of genetically modified feed/food.
Recently, the Genetically Modified Organisms unit was mandated by EFSA to prepare an explanatory statement supporting EFSA's 'Guidance on conducting repeated-dose 90-day oral toxicity study in rodents on whole food/feed' in the frame of Implementing Regulation (EU) 503/2013. Some of the major modifications to the current OECD 408 study design include blinding of test diets, social housing, inclusion of multiple dose levels, proposal of maximum incorporation rate (high dose level) for various crops, justification of samples size based on effect size of toxicological relevance, and combined gender statistical analyses. The appropriateness and applicability of these additional EFSA recommendations are discussed in elsewhere (Hong et al., 2017) . Dow AgroSciences, LLC in collaboration with MS Technologies, L.L.C developed a transgenic soybean event, DAS-444Ø6-6 to offer farmers alternative options to combat weeds. Expression of (aryloxyalkanoate dioxygenase-12) provides tolerance to 2,4-diclorophenoxyacetic acid (2,4-D), expression of 2mEPSPS (double-mutated maize 5-enolpyruvyl shikimate-3-phosphate synthase) provides tolerance to glyphosate, and expression of PAT (phosphinothricin acetyl transferase) provides tolerance to glufosinate (Naegeli et al., 2017; Papineni et al., 2017) .
Previously, two 90-day feeding studies were conducted in rats with diets containing 20% soybean meal to evaluate the safety of DAS-444Ø6-6 soybeans; the second study also incorporated hulls and oil derived from DAS-444Ø6-6 soybeans (Naegeli et al., 2017; Papineni et al., 2017) . No treatment-related effects were reported in these studies supporting the safety of DAS-444Ø6-6 soybean. With the emerging new regulatory requirements related to the 90-day toxicity study design and the uncertainty about the acceptability of the previous studies, a new study was conducted in accordance with all the new considerations stated by EFSA in their guidance documents (EFSA, 2011; EFSA, 2014) . Following these considerations laid out by EFSA, groups of 16 male and 16 female Sprague-Dawley rats were each fed diets containing 15% or 30% meal, 1% or 2% hulls, and 1.35% or 2.7% of oil from DAS-444Ø6-6 soybean, respectively, for low-and high-dose groups. Number of rats per group was selected based on EFSA's recommendations in EFSA, 2011 guidance on the sample sizes based on power analysis to have sufficient power to detect a standardized effect size (SES) of approximately one standard deviation or less. Therefore, sixteen rats per sex per group with two animals per cage, and a randomized block design with three treatment groups (control, low and high) was chosen to have sufficient power in this study. Explanatory statement from EFSA on the guidance for conducting 90-day feeding studies (EFSA, 2014) recommends that the test diets should adequately represent the wholeness of the food/feed. Thus, fractions such as hulls and oil derived from the grain could be formulated into test diets in amounts that will meet the recommended nutrition requirements for rodent diets. For soybeans, hulls and oil are plant by-products that are used as food and or feed and therefore added to the test diets in this study.
Materials and methods

Animal welfare
The animal care and use activities required for conduct of this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) in accordance with the US Department of Agriculture animal welfare regulations, 9 CFR, Subchapter A, Parts 1-4. The animal facility is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.
Animals
Male and female Crl:CD(SD) rats (Sprague-Dawley derived), were obtained from Charles River Laboratories Inc. (Raleigh, North Carolina). Animals were stratified by body weight and randomly assigned to groups by a computer program. At the start of the study, animals were approximately 7 weeks old with males weighing between 254.2 and 326.3 g and females weighing between 158.2 and 220.9 g. The animals were housed in stainless steel solid bottom cages with corncob bedding. Cages contained a feed crock and a pressure activated lixit valve-type watering system. Environmental conditions targeted were: temperature of 22 ± 1°C (maximum permissible excursion of ± 3°C), 40-70% relative humidity, 12/12 h light/dark photocycle, and a room air exchange of 10-15 times/h. Enrichment for rats included paired housing and open areas on the cage sides for visualization of other rats. In addition, one or two nylon bones were added to each cage, and were replaced as needed throughout the study. Enrichment was given to all animals from the day of arrival until necropsy.
Feed and water
Feed and water were provided ad libitum during acclimation and throughout the study. Analysis of the test diets and water was performed as described previously (Papineni et al., 2017) .
Soybean diets
EFSA provided reference values for high dose incorporation rates for different crops in their explanatory statement which represent the maximum incorporation rate not causing nutritional imbalance. For soybeans, they recommended 30% for defatted soybean meal or 20% if fullfat soybean meal is used. Soybean meal contains approximately 48% crude protein. Rodent diets vary in crude protein content between 15 and 20%, which would limit the inclusion of soybean meal to approximately 30% assuming remaining ingredients contribute little protein to the overall diet to avoid protein excess. The Purina Test Diet 5002, the diet upon which the majority of 90-day rodent studies are based on, is formulated to provide 20% crude protein and therefore, 30% inclusion rate of soybean meal is consistent with the upper bound of inclusion. Following this guidance, the test diets were formulated at Purina Test Diet (Richmond, IN) by mixing DAS 444Ø6-6 soybean meal into the standard recipe for LabDiet Certified Rodent Diet 5002 (PMI Nutrition International, St. Louis, MO) at a 15% or 30% w/w concentration. Soybean hulls (1% or 2%) and oil (1.35% or 2.7%) derived from DAS-444Ø6-6 soybeans were also added to low-and hightest diets, respectively. The low-dose test diet (15% DAS-444Ø6-6) contained 50% of the maximum inclusion level of soybean meal, hulls, and oil as transgenic ingredients, but was brought up to respective maximal levels using near-isogenic non-transgenic soybean meal. In addition, four control diets were prepared with 30% soybean meal, 2% hulls, and 2.7% of oil from an isogenic non-transgenic control and three commercial reference control soybeans. All diets were formulated to be balanced in nutrition and meet the energy requirements for the animals. There is currently no practical method available to determine the homogeneity, stability, or concentration of the test or isogenic control substance in formulated diets. However, the supplier of the formulated diets (PMI TestDiet) has provided information that demonstrates that adequate homogeneity was achieved by the diet mixing equipment and the procedures used for preparing the diets. The test and isogenic control substance diets were formulated according to the specifications for PMI Certified Rodent LabDiet ® 5002 (meal), with the exception of the test or isogenic control substance meal inclusion rate. The diets, however, did meet the nutritional composition requirements specified for LabDiet ® 5002. In addition, PMI TestDiet provided gravimetric information indicating that the diets were prepared at the targeted concentrations. PMI TestDiet has also provided information indicating that the PMI Certified Rodent LabDiet ® 5002 (meal) is stable for at least 6 months from the time of preparation. The in-life portion of this study was completed within 6 months of diet preparation. Diet preparations, storage and analysis was conducted as described previously (Papineni et al., 2017) .
Blinding of test diets
Purina Test Diets (Richmond, IN) assigned a 4-digit and a 10-digit alpha-numeric code to each of the test and control diets to blind the identity of the diets to the study personnel. No identifying codes other than study number were known to study personnel. The identity of the diets was revealed only after the in-life portion of the study and necropsies were completed.
Study design
Groups of 16 male and 16 female Sprague-Dawley rats were fed test diets containing 15% or 30% soybean meal with hulls and oil for 90 days. Cage-side observations, detailed clinical observations, ophthalmic examinations, functional tests, body weights/body-weight gains, feed consumption, hematology and coagulation parameters, clinical chemistry, urinalysis, and organ weights were evaluated. In addition, a complete necropsy was conducted and extensive histopathologic examination of tissues was performed. The eyes of all animals were examined pre-exposure and prior to the scheduled necropsy. A cage-side examination was conducted at least once a day. All animals were observed for morbidity, mortality, and the availability of feed and water at least twice daily. Detailed clinical observations (DCO) were made pre-exposure and weekly throughout the study on all animals. This examination included cage-side, hand-held, and open-field observations that were recorded categorically or using explicitly defined scales (ranked). All rats were weighed during the pre-exposure period and weekly thereafter. Body weight gains were calculated relative to test day 1. Feed consumption was determined pre-exposure and twice weekly for all animals. Test material intake was calculated. In addition to the recent EFSA guidance, the following guidelines were also consulted during the design of the study: OPPTS 870.3100 (US-EPA, 1998), OECD Guideline No. 408 (OECD, 1998 ), Part B.26, Directive 2001 /59/ EC (EC, 2001 and Subchronic Oral Toxicity Study (JMAFF, 2000) . This study was conducted under Good Laboratory Practice (GLP) Standards, with the exception of diet preparation by Purina Test Diet.
2.7. Functional tests, sensory evaluation, rectal temperature, and grip performance Functional tests (sensory evaluation, rectal temperature, grip performance, and motor activity) were conducted pre-exposure and near the end of the treatment period for all animals. The sensory evaluation included a test for nociception (responsiveness to tail pinch) and for startle response (responsiveness to sharp noise). The evaluation was conducted in a clear plastic box. Rectal temperature was measured by carefully placing a rectal thermistor (Physitemp, Clifton, New Jersey) approximately 4 cm into the rectum for approximately 10 s.
Hindlimb grip performance was tested according to the procedure described by Mattsson et al. (1986) . Briefly, the observer placed the rat's forelegs on a plastic bench and the hindfeet were set on a horizontal screen attached to an electronic strain gauge (Chatillon, Greensboro, North Carolina). The observer then smoothly but firmly pulled backward on the tail until the rat's grip on the screen was broken. An electronic strain gauge was used to record the rat's resistance to the pull in grams. The average of three trials was used for statistical analysis. Forelimb grip performance was similarly tested. In this application, a bench was not used, and the rats were placed so that the forefeet were on the screen and the hindfeet were suspended approximately 10 cm above the plastic platform.
Hematology and coagulation
Animals were fasted overnight prior to blood collection. Blood samples were obtained from the orbital sinus following anesthesia via inhalation of O 2 /isoflurane at the scheduled necropsy. Blood samples were mixed with ethylenediaminetetraacetic acid (EDTA) and assayed for all hematological parameters as described previously (Papineni et al., 2017) . Blood samples were collected in sodium citrate tubes, centrifuged, and plasma collected and assayed for prothrombin time (PT) and activated partial thromboplastin time (APTT) using an ACL9000 coagulation analyzer (Instrumentation Laboratory, Bedford, Massachusetts).
Clinical chemistry and urinalysis
Collection of blood samples, serum separation, measurement of clinical chemistry parameters, and collection and analysis of urine samples were accomplished per procedures described previously (Papineni et al., 2017) .
Necropsy and histopathology
Fasted rats were anesthetized with a mixture of isoflurane vapors and medical grade oxygen, weighed, and blood samples were obtained prior to euthanasia. A complete necropsy was conducted on all animals by a veterinary pathologist assisted by a team of trained individuals. The brain, liver, kidneys, heart, adrenals, testes, epididymides, uterus, ovaries, thymus, and spleen were trimmed and weighed immediately. The thyroid gland with the parathyroid was weighed post-fixation. The ratios of organ weight to terminal body weight were calculated. Representative samples of 56 tissues were collected and preserved in neutral, phosphate-buffered 10% formalin in accordance with the previously cited guidelines. Sections from all preserved tissues were processed by standard histologic procedures from control (near-isogenic non-transgenic control and DAS-444Ø6-6 (30%) test animals). Paraffin embedded tissues were sectioned approximately 6 μm thick, stained with hematoxylin and eosin, and examined by a veterinary pathologist using a light microscope.
Statistics
The DAS-444Ø6-6 diet groups were independently compared with the near-isogenic non-transgenic control group. Cage was considered the experimental unit for body weights, feed consumption, organ weights, urine volume, urine specific gravity, clinical chemistry data, coagulation, and appropriate hematologic data. These parameters were first evaluated by Bartlett's test (alpha = 0.01; Winer et al. (1971) ) for homogeneity of variances and data was transformed to achieve homogeneity of variance, if necessary.
Data analysis for body weights, feed consumption, organ weights, urine volume, urine specific gravity, clinical chemistry data, coagulation, and appropriate hematologic data were performed by a two-way ANOVA (Steel and Torrie, 1960) with the factors of sex, test diet, the interaction of sex by test diet and the blocking factor of necropsy week in the model (except for testes, epididymides, uterus, and ovaries weights). When the interaction was significant at alpha = 0.05, the analyses were run separately for each sex. Testes, epididymides, uterus and ovaries weights were analyzed by a one-way ANOVA with the factor of test diet and the blocking factor of necropsy week in the model. When the test diet effect was significant at alpha = 0.05, the ANOVA was followed by Dunnett's test (Winer et al., 1971) . The corrected alpha level of 0.05 was reported.
Descriptive statistics only (means and standard deviations) were reported for body weight gains, globulin, albumin/globulin ratio, and RBC indices. Statistical outliers were identified by a sequential test (alpha = 0.02; Grubbs (1969) ), but routinely excluded only from feed consumption statistics.
Neurobehavioral data have greater inter-animal variability than other measures. In these cases, the impact of inherent inter-animal differences likely outweighs the effect of cage on variability and generating a mean cage value for neurobehavioral data results in a loss of information. Therefore, neurobehavioral endpoints were statistically analyzed with the individual animal as the unit of analysis.
DCO incidence data (scored observations only) and sensory evaluation incidence data (scored observations only) were statistically analyzed by a z-test of proportions comparing each test diet with the control group (alpha = 0.05; Bruning and Kintz (1987) ). Data collected at different time points and from different sexes were analyzed separately as the z-test cannot test interactions to determine if it is appropriate to combine.
Rectal temperature and grip performance data were analyzed by a factorial analysis of covariance (ANCOVA) with the factors of sex and test diet and the covariate of the pre-exposure time point measure of the variable (Steel and Torrie, 1960) . The first examination in the ANCOVA was for the test diet-by-pre-exposure measure interaction. If the interaction was not significant, the second examination for ANCOVA was to determine whether the sex-by-test group interaction was significant at alpha = 0.05; if it was, a one-way ANCOVA was done separately for each sex. When there was a significant test diet group effect (alpha = 0.05), least squares means were generated and a t-test done to compare the individual test diet groups with the control group. The comparison-wise error rate was set to alpha = 0.02 to correct for multiple comparisons with the control. In the ANCOVA, if the test group-by-pre-exposure measure interaction was significant at alpha = 0.05, a factorial repeated-measures ANOVA, the multivariate approach, with factors of sex and test diet and the repeated factor of time were run.
Motor activity data were analyzed by a factorial repeated-measure design, the multivariate approach, with factors of sex and test diet and the repeated factor of time. Motor activity also had the repeated factor of interval (within time) in the model. The inclusion of pre-exposure data in the analysis makes relevant only the analyses that include factors of both test diet and time. The primary interactions examined at alpha = 0.05 were test diet-by-time-by-sex, test diet-by-time, and test diet-by-time-by-interval. In the repeated-measure ANOVA with a preexposure data point, the test diet-by-time interaction assesses the true effect of treatment (Bonate, 2000) whereas the test group-by-time-byinterval reflects the effects of the test compound on the distribution of motor activity over time. The statistical significance of the test diet-bytime-by-sex interaction was examined first. If significant, the analysis was repeated separately for each sex. The test diet-by-time interaction and the test group-by-time-by-interval interaction were then examined. If either was significant, linear contrasts were calculated to determine which test groups were different from the control group. The comparison-wise error rate was set to alpha = 0.02 to correct for multiple comparisons to the control. The Pillai's Trace p-values were reported without correction. This overall approach of primary planned analyses being conducted at alpha = 0.05 and the linear contrasts being conducted at alpha = 0.02 was consistent with the recommendations proposed by Tukey et al. (1985) , Mantel (1980) , and by the US-EPA (1991).
Results
Survival and clinical observations
All animals given near-isogenic non-transgenic control or DAS-444Ø6-6 test diets at 15% or 30% survived until the scheduled necropsy. There were no clinical findings or scored DCO observations that were related to consumption of DAS-444Ø6-6 soybean.
Functional tests
There were no effects on the sensory evaluation that were related to consumption of DAS-444Ø6-6 soybean. There were no treatment-related effects on rectal temperature. The treatment by sex interaction for rectal temperature was not significant (p = .7824), which indicated that there were no treatment-related sex differences. The main effect of treatment was also not significant (p = .0658).
There were no treatment-related effects on grip performance. The treatment by sex interaction was not significant for either hindlimb (p = .6273) or forelimb (p = .2060) grip performance which indicated that there were no treatment-related sex differences in grip performance. The main effect of treatment was also not significant for hindlimb (p = .1217) or forelimb (p = .6353) grip performance, which indicated that exposure to DAS-444Ø6-6 soybean did not affect grip performance in rats.
There were no treatment-related effects on motor activity. The treatment by time by sex interaction was not significant (p = .2071), which indicated that there was not a treatment-related sex difference in motor activity at either time point. There was a significant primary treatment by time interaction (p = .0491); however, the linear contrasts (alpha = 0.02) indicated no significant differences from control at either the 15% (p = .0246) or 30% (p = .0473) dietary concentration. In addition, review of data indicates that there were no treatmentrelated effects on total motor activity at either dietary concentration of DAS-444Ø6-6. Furthermore, the treatment by time by interval interaction was not significant (p = .2530), which indicated that exposure to DAS-444Ø6-6 soybean did not affect the within-session distribution of motor activity counts at either time point. Data for functional tests is not shown.
Ophthalmological observations
There were no treatment-related ophthalmological findings associated with the consumption of diets containing DAS-444Ø6-6 soybean (Data not shown). Ophthalmological observations on test day 82 consisted of pale fundus in one female rat in the group fed 30% DAS-444Ø6-6, and in three males (two in the group fed diets containing 15% DAS-444Ø6-6 soybean, and one in the group fed diets containing 30% DAS-444Ø6-6 soybean). This observation was interpreted to be unrelated to treatment due to the low incidence and lack of a dose-response relationship. All other rats were within normal limits.
Body weights/body weight gain
There were no treatment-related differences in body weights or body weight gains in male or female rats given DAS-444Ø6-6 soybean when compared with the near-isogenic non-transgenic controls (Figs. 1 and 2; Tables 1 and 2). Males given 30% DAS-444Ø6-6 soybean meal had lower body weights (3.8-7.2%) and body weight gains relative to test day 1 (10.6-15.2%) for most of the duration of the study compared with the near-isogenic non-transgenic control males. However, these body weight differences from control did not reach statistical significance when analyzed using a two-way ANOVA. The lower body weights and body weight gains corresponded with lower feed consumption in this group as compared with the near-isogenic non-transgenic controls (Figs. 1-4 ). These differences were interpreted as normal biological variability because these lower feed consumption values, body weights, and body weight gains were similar to males given one of the commercial reference control soybean meal varieties (Variety B), and therefore, the observations were interpreted to be unrelated to the exposure to DAS-444Ø6-6 soybean. Moreover, body weights/body weight gains and feed consumption values of females given 30% w/w DAS-444Ø6-6 soybean were similar to the near-isogenic non-transgenic control group.
Feed consumption
There were no treatment-related differences in feed consumption values in male or female rats given DAS-444Ø6-6 soybean when compared with the near-isogenic non-transgenic controls. Males given 30% DAS-444Ø6-6 soybean meal had slightly lower feed consumption values which were statistically identified at some of the time-points (days 57-60, 67-71, and 74-78) during the study as compared with the nearisogenic non-transgenic control males (Fig. 3) . These lower feed consumption values were, however, interpreted to reflect normal biological variability because they were similar to the group given one of the commercial reference control soybean meal varieties, and the observed values were within the laboratory's historical control range. Therefore, these lower feed consumption values were interpreted to be unrelated to the exposure to DAS-444Ø6-6 soybean. Moreover, females given 30% w/w DAS-444Ø6-6 soybean meal had no statistically-identified differences compared with the near-isogenic control (Fig. 4) .
Hematology and coagulation
There were no statistically-identified or treatment-related effects in any of the hematological parameters in males or females given DAS-444Ø6-6 soybean meal as compared with the near-isogenic non-transgenic control (Tables 3 and 4 ). There were no treatment-related effects in activated partial thromboplastin time (APTT) in males or females given DAS-444Ø6-6 soybean meal as compared with the near-isogenic non-transgenic control. Prothrombin time (PT) was statistically higher (when analyzed by two-way ANOVA) for both sexes given 15% w/w DAS-444Ø6-6 soybean meal as compared with the near-isogenic nontransgenic control. However, the higher PT values were within the commercial reference control range and there was no dose-response relationship, and hence, it was interpreted to be spurious and unrelated to exposure to DAS-444Ø6-6 soybean meal (Table 5) .
Clinical chemistry
There were no treatment-related differences in any of the clinical chemistry parameters in males or females given DAS-444Ø6-6 soybean meal (Tables 6 and 7 ). Mean urea nitrogen was statistically identified as lower (when analyzed by two-way ANOVA) for both sexes given 30% w/w DAS-444Ø6-6 soybean meal as compared with the near-isogenic non-transgenic control. However, it was within the commercial reference control range and the laboratory's recent historical control range (Table 8) , and therefore, this minimal difference was interpreted to be spurious and unrelated to the exposure to 30% w/w DAS-444Ø6-6 soybean meal. Moreover, there were no treatment-related histopathological effects in the kidneys of males or females given 30% w/w DAS-444Ø6-6 soybean meal. There were no statistically-identified or treatment-related effects in any other serum clinical chemistry parameters in males or females given DAS-444Ø6-6 soybean meal as compared with the corresponding near-isogenic non-transgenic controls. There were no treatment-related differences in any of the urinalysis parameters for males or females given DAS-444Ø6-6 soybean meal as compared with the corresponding near-isogenic non-transgenic controls.
Organ weights and gross pathology and histopathology
There were no treatment-related effects in terminal body weights or any of the organ weights in males and females (analyzed together) given DAS-444Ø6-6 soybean meal as compared with the near-isogenic non-transgenic control (Tables 9 and 10 ). There were no statisticallyidentified differences in terminal body weights or organs weights in males given DAS-444Ø6-6 soybean meal compared with the near isogenic controls; however, in females given 15% DAS-444Ø6-6 soybean meal, the mean relative ovary weight was statistically and marginally lower than that of the near-isogenic non-transgenic control females. This was interpreted to be unrelated to treatment due to lack of a doseresponse relationship. Moreover, this value was also very close to the commercial reference control range and was within the laboratory's recent historical control range (Table 11 ). There were no treatmentrelated gross pathological or histopathological observations. All the pathological observations were interpreted to be spontaneous alterations, unassociated with exposure to the genetically modified DAS-444Ø6-6 soybean.
Discussion
DAS-444Ø6-6 is a genetically modified soybean which expresses proteins. The aryloxyalkanoate dioxygenase-12 (AAD-12) enzyme inactivates 2,4-diclorophenoxyacetic acid (2,4-D) herbicide, the 2mEPSPS (5-enolpyruvylshikimate-3-phosphate synthase) is insensitive to glyphosate herbicide, and the phosphinothricin acetyltransferase (PAT) enzyme provides tolerance to glufosinate-ammonium herbicide. It is noteworthy that DAS-444Ø6-6 soybean did not show any biologically relevant changes in the crop compositional analyses (Fast et al., 2016; Lepping et al., 2013; Herman and Price, 2013 ) that would require any further toxicological assessment. However, in contrast to EFSA's position that animal feeding studies should be hypothesis driven, the new implementing regulation No. 503/2013 in Europe made subchronic animal feeding studies as mandatory for single events irrespective of any hypothesis (EC, 2013) .
In spite of lacking a specific hypothesis, two subchronic toxicity studies were conducted in 2012 and 2013 to comply with changing regulatory requirements in Europe. The first study in 2012 was conducted by feeding 12 Sprague-Dawley rats/sex/group diets formulated with 20% w/w of dehulled/defatted toasted soybean meal from DAS-444Ø6-6. No adverse effects were observed in this study and this conclusion was consistent with the EFSA GMO panel's review of the study (Naegeli et al., 2017) . Another 90-day study conducted in 2013 assessed two dose levels using 12 male and 12 female Sprague-Dawley rats fed with diets containing 10% or 20% DAS-444Ø6-6 soybean meal with hulls (1% or 2%). Consistent with the results of the previous 2012 study, no treatment-related effects were reported in this second study (Papineni et al., 2017) . Although conducted in accordance with OECD 408, these studies did not follow the updated recommendations made by EFSA in the guidance on conducting 90-day studies in rodents (EFSA, 2011; EFSA, 2014) . Some of the deviations from EFSA recommendations included lack of social housing, lack of inclusion of multiple dose levels (in 2012 study), lack of blinding of test diets, lack of functional tests, not testing at maximum incorporation rates as proposed by EFSA for soybean (30% for dehulled defatted soybean meal) and other modifications related to statistical analyses. With the lack of specific criteria that might trigger these requirements, ambiguity exists in how EFSA might interpret the guidance in the future. Therefore, a new study was conducted following the study design currently described by EFSA. Results from this third 90-day rat study also showed that DAS-444Ø6-6 soybean caused no treatment-related effects.
Conclusions
The results of this study conducted with DAS-444Ø6-6 soybean were &Indicates no statistical comparison of means. Fig. 3 . Mean feed consumption summary -males. No statistically significant differences were observed. Fig. 4 . Mean feed consumption summary -females. No statistically significant differences were observed. in full adherence to recent EFSA guidance. DAS-444Ø6-6 did not cause any treatment-related effects in clinical signs, ophthalmic observations, functional tests, motor activity, body weights/body-weight gains, feed consumption, hematology, coagulation, clinical chemistry, urinalysis, selected organ weights, or gross and histopathologic examinations as compared with rats fed diets with 30% w/w near-isogenic non-transgenic control or diets prepared with commercially available reference varieties. Any changes observed were unrelated to the treatment and either did not demonstrate a dose-response or were within or close to the commercial reference control range or the laboratory's historical control ranges. The outcome of this study was consistent with the results of the previous subchronic studies and also supports the scientific opinion published by EFSA that DAS-444Ø6-6 soybeans are as safe and nutritious as non-GM soybeans (Naegeli et al., 2017) . The results of this study also support the observation that, to date, there is no evidence of GM food or feed causing any adverse effects or having any potential risk for consumers (Bartholomaeus et al., 2013; Bren, 2002; Hong et al., 2017; National Academies of Sciences and Medicine, 2016; Zeljenková et al., 2014) . a TBIL lowest detection limit is 0.15. Individual values < 0.15 were reported as 0.08 (one-half the detection limit rounded) for statistical analysis. b CREA lowest detection limit is 0.2. Individual values < 0.2 were reported as 0.1 (one-half the detection limit) for statistical analysis. c GGT lowest detection limit is 3.0. Individual values < 3.0 were reported as 1.5 (one-half the detection limit) for statistical analysis.
Table 7
Clinical chemistry summary -females. a TBIL lowest detection limit is 0.15. Individual values < 0.15 were reported as 0.08 (one-half the detection limit rounded) for statistical analysis. b CREA lowest detection limit is 0.2. Individual values < 0.2 were reported as 0.1 (one-half the detection limit) for statistical analysis. c GGT lowest detection limit is 3.0. Individual values < 3.0 were reported as 1.5 (one-half the detection limit) for statistical analysis. 
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